Mizuho Medy Co.,Ltd. (TYO:4595)

Market Cap	34.44B +18.2%
Revenue (ttm)	11.26B -1.5%
Net Income	3.43B -9.2%
EPS	179.80 -9.2%
Shares Out	19.05M
PE Ratio	10.06
Forward PE	n/a
Dividend	100.00 (5.50%)
Ex-Dividend Date	Jun 29, 2026

Volume	75,100
Average Volume	63,520
Open	1,817.00
Previous Close	1,818.00
Day's Range	1,801.00 - 1,823.00
52-Week Range	1,402.00 - 1,930.00
Beta	0.50
RSI	45.88
Earnings Date	May 8, 2026

About Mizuho Medy

Mizuho Medy Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products, and related scientific and technical information services in Japan. The company offers molecular diagnostic products, such as nucleic acid amplification test products comprising gene analysis instruments and mycoplasma pneumoniae nucleic acid kits. It also provides rapid immunoassay products, including influenza virus antigen test kit; RS virus and human metapneumovirus antigen test kit; streptococcus pneumoniae antigen and legio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1977
• Employees: 193
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4595

Financial Performance

In 2025, Mizuho Medy's revenue was 11.26 billion, a decrease of -1.48% compared to the previous year's 11.43 billion. Earnings were 3.43 billion, a decrease of -9.22%.